Proton Pump Inhibitors (PPIs) Market to Grow by USD 819.5 Million (2025-2029) with Drug Reformulation Boosting the Market, Report on How AI is Redefining Market Landscape - Technavio

NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The globalproton pump inhibitors (PPIs) marketsize is estimated to grow by USD 819.5 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Reformulation of drugsis driving market growth,with a trend towardsgrowing geriatric population. However,increasing lawsuits against PPIs poses a challenge. Key market players include Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Proton Pump Inhibitors (PPIs) are popular acid-suppressing medications used to treat various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive issues. These medications work by reducing the production of stomach acid, targeting the gastric proton pump. The market for PPIs is on the rise due to an aging population, sedentary lifestyles, poor dietary choices, irregular eating patterns, stress, and obesity. Key players in the market include branded PPIs like Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole, as well as generic versions. Healthcare investment is booming in this area due to the growing demand for pharmaceutical solutions for gastrointestinal health. However, safety concerns and the availability of over-the-counter (OTC) drugs and hospital pharmacies present challenges for branded PPIs. The use of molecular biology, genomics, artificial intelligence, and big data analytics in the development of personalized medicine approaches is a trend in the industry. The World Health Organization has set guidelines for the use of PPIs, and regulatory bodies are closely monitoring safety concerns. The market is expected to grow significantly in the coming years due to increasing healthcare expenditure, a middle class with disposable incomes, and the availability of various drug formulations, including oral and injectable options. Direct-to-consumer advertising and the availability of PPIs in retail pharmacies and drug stores are also contributing to the market's growth.

The aging population is a significant driver for the global Proton Pump Inhibitors (PPIs) market due to the increased prevalence of gastroesophageal reflux disease (GERD) and acidity with age. The esophageal sphincter, which prevents stomach acid from flowing back into the esophagus, weakens with age, leading to heartburn and acid reflux. Additionally, the digestive system slows down, further contributing to acidity. As the population ages, the incidence of these conditions is expected to rise, boosting market growth for PPIs.

Request Sampleof our comprehensive report now to stay ahead in the AI-driven market evolution!

• Proton Pump Inhibitors (PPIs) market is witnessing significant growth due to the rising prevalence of acid-related disorders, particularly gastroesophageal reflux disease (GERD). Acid secretion is a natural process, but its excess can lead to conditions like peptic ulcers and acid reflux. PPIs inhibit the gastric proton pump, reducing stomach acid production. The market faces challenges from poor dietary choices, sedentary lifestyles, stress, and an aging population. Middle and upper-class populations with disposable incomes are major consumers, driving healthcare expenditure. Molecular biology, genomics, artificial intelligence, and big data analytics are transforming PPI development. Branded PPIs like Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole dominate the market, but safety concerns and generic versions pose challenges. The WHO recommends personalized medicine approaches for effective therapy. Dexlansoprazole is available in oral and injectable forms for various indications. Obesity, irregular eating patterns, and sedentary work cultures further fuel demand. Direct-to-consumer advertising and retail pharmacies/drug stores expand accessibility. Patents, hospital pharmacies, and OTC drugs also impact the market dynamics. Despite challenges, the future of PPIs lies in pharmaceutical solutions for gastrointestinal health.
  
  
• The Proton Pump Inhibitors (PPIs) market is currently facing legal challenges due to allegations that certain PPIs, such as PREVACID and DEXILANT, cause kidney injuries. Plaintiffs claim that manufacturers, including Takeda Pharmaceuticals, failed to adequately warn consumers about the potential risks. The FDA requested the withdrawal of all ranitidine products due to the potential formation of NDMA, a carcinogen, during storage and distribution. Other PPI manufacturers, including AstraZeneca, Pfizer, and Procter and Gamble, are also facing similar lawsuits. These developments may impact the market growth and consumer trust in PPIs.

Discover how AI is revolutionizing market trends-Get your access now!

This proton pump inhibitors (ppis) market report extensively covers market segmentation by

• Product
• OTC PPIs
• Prescription PPIs
• Route Of Administration
• Oral
• Injectable
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

1.1OTC PPIs- The over-the-counter (OTC) Proton Pump Inhibitors (PPIs) market has experienced significant growth in recent years due to the easy accessibility and affordability of these medications. OTC PPIs, such as PREVACID, NEXIUM, PRILOSEC, and Zegerid, are used for treating frequent heartburn by decreasing acid secretion in the stomach. Heartburn is a condition characterized by the backflow of stomach content into the esophagus, resulting in a burning sensation in the chest. OTC PPIs are intended for use for up to 14 days per year, according to the US Food and Drug Administration (FDA). The convenience of self-medication and cost savings associated with OTC PPIs have led to an increase in their usage. This trend is expected to continue, driving the growth of the OTC PPIs segment in the global Proton Pump Inhibitors market.

Download a Sampleof our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Proton Pump Inhibitors (PPIs) are a type of acid-suppressing medication widely used for managing various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions where reducing stomach acid secretion is essential. These medications inhibit the gastric proton pump, thereby decreasing the production of stomach acid. PPIs are available in various drug formulations, including oral and injectable, and are used to treat both prescription and over-the-counter (OTC) indications. Lansoprazole, Esomeprazole, Rabeprazole, Pantoprazole, and Dexlansoprazole are some common PPIs. The market for PPIs is driven by the growing prevalence of acid-related disorders due to poor dietary choices, sedentary work cultures, stress, and aging population. Personalized medicine approaches are also being explored to optimize the use of PPIs and improve gastrointestinal health. The healthcare investment in pharmaceutical solutions for acid-related disorders continues to grow, making PPIs a significant market segment.

Proton Pump Inhibitors (PPIs) are a type of acid-suppressing medication widely used to manage various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive issues. These medications work by inhibiting the gastric proton pump, which in turn reduces stomach acid production. PPIs have become increasingly popular due to the aging population, irregular eating patterns, sedentary lifestyles, stress, and poor dietary choices that contribute to acid reflux and other GI health problems. The market for PPIs is significant, driven by the middle class with disposable incomes and rising healthcare expenditure. Molecular biology, genomics, artificial intelligence, and big data analytics are transforming the development of personalized medicine approaches for PPIs. Safety concerns, patents, and the availability of generic versions also impact the market dynamics. Branded PPIs include Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole, available in various formulations such as capsules, injectables, and OTC drugs. The market faces competition from hospital pharmacies, retail pharmacies, and drug stores. The World Health Organization the importance of addressing the global burden of acid-related disorders, making PPIs a crucial area of investment in pharmaceutical solutions. However, obesity and safety concerns remain significant challenges for the industry.

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
• OTC PPIs
• Prescription PPIs
• Route Of Administration
• Oral
• Injectable
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[emailprotected]
Website:www.technavio.com/

SOURCE Technavio